

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

Alba Guglielmo,^{1,2} Maria Ludovica Deotto,³ Luigi Naldi,⁴ Giuseppe Stinco,^{2,5} Alessandro Pileri,¹ Bianca Maria Piraccini,¹ Anna Belloni Fortina,³ Andrea Sechi⁴

¹Dermatology Unit, IRCCS University Hospital of Bologna, Policlinico S. Orsola-Malpighi, Bologna;

²Institute of Dermatology, Azienda Sanitaria Universitaria Friuli Centrale, Udine; ³Dermatology Unit, Department of Medicine, University of Padova; ⁴Dermatology Unit, San Bortolo Hospital, Vicenza; ⁵Department of Medicine, University of Udine, Italy

Abstract

This comprehensive review offers a detailed look at atopic dermatitis (AD) treatment in Italy, focusing primarily on the use of biologics and small molecules. In response to advancing knowledge of AD's causes and treatments, there's a global need for updated guidelines to provide physicians with a more comprehensive clinical perspective, facilitating personalized treatment strategies. Dupilumab, a groundbreaking biologic, gained approval as a significant milestone. Clinical trials demonstrated its ability to significantly reduce AD severity scores, with an impressive 37% of patients achieving clear or nearly clear skin within just 16 weeks of treatment. Real-world studies further support its efficacy across various age groups, including the elderly, with a safety profile akin to that of younger adults. Tralokinumab, a more recent approval, shows promise in clinical trials, particularly among younger populations. However, its real-world application, especially in older individuals, lacks comprehensive data. Janus Kinases inhibitors like Upadacitinib, Baricitinib, and Abrocitinib hold substantial potential for AD treatment. Nevertheless, data remains limited for patients over 75, with older adults perceived to carry a higher risk

profile. Integrated safety analyses revealed individuals aged 60 and above experiencing major adverse cardiovascular events and malignancies, underscoring the need for cautious consideration. While these therapies offer promise, especially among younger patients, further research is essential to determine their safety and efficacy in various populations, including pediatric, geriatric, and those with comorbidities. Biologics and small molecules are improving AD treatment, as shown in this review.

Introduction

Atopic dermatitis (AD) is a chronic relapsing and remitting, pruritic, inflammatory skin disease affecting both children and adults. Patients with moderate-to-severe AD who fail first-line systemic traditional therapies, such as cyclosporine A, may be considered for biologic or small molecules therapy. Biologics and small-molecules currently approved in Italy for the treatment of moderate-to-severe AD include dupilumab (DUP), tralokinumab (TRA), upadacitinib (UPA), abrocitinib (ABR) and baricitinib (BAR). Data from clinical trials, real-world studies, and case series provide information on the safety and efficacy of these treatments also in special populations of patients.¹

This paper aims to summarize the literature and create an evidence-based treatment algorithm for moderate-to-severe AD in patients with comorbidities and special populations (Table 1), including those with T helper (Th) 2 atopic comorbidities,¹ past and current infections,² arthritis and inflammatory bowel diseases,³ other autoimmune or inflammatory skin diseases,⁴ previous history of cancer,⁵ childbearing and breastfeeding potential,⁶ pediatric and adolescent patients,⁷ and elderly patients.⁸

T helper 2 atopic comorbidities

Type 2 inflammation is driven by Th2 cells and group 2 innate lymphoid cells, which produce the type 2 cytokines, like interleukin (IL)-4, IL-5 and IL-13, and other inflammatory mediators. A number of atopic conditions, including AD, rhinitis, asthma and chronic rhinosinusitis with nasal polyps, are characterized by type 2 inflammation. For appropriate disease treatment and improving overall patient outcomes, identifying AD comorbidities is important.

Asthma

AD is typically the initial manifestation of an atopic diathesis, which affects people with a hereditary predisposition and also includes asthma and rhinitis. Asthma or rhinitis could develop in children with AD up to 80% of the time.² The worldwide prevalence of asthma symptoms caused by atopic sensitization was 30% in adults and ranged with a large international variation from 0%

Correspondence: Alba Guglielmo, Institute of Dermatology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Piazzale Santa Maria della Misericordia 15, Udine, 33100, Italy.
E-mail: albaguglielmo@gmail.com

Key words: atopic dermatitis; biologic; anti-interleukin; small-molecules; JAK inhibitors.

Conflict of interest: the authors declare no potential conflict of interest.

Received: 29 August 2023.

Accepted: 30 August 2023.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2023

Licensee PAGEPress, Italy

Dermatology Reports 2024; 16:9839

doi:10.4081/dr.2023.9839

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

to 93.8% in children. In Italy, the fraction of current asthma attributable to atopy in pediatric patients was 56.2%.³⁻⁵ For the treatment of asthma, various biologics that target Th2 pathways have been approved. The most appropriate biologic for treating asthma depends on age, comorbidities, treatment objectives and exacerbation triggers.⁶ Due to the overlapping functions of IL-4 and IL-13, biologics that target just one of these molecules are not effective in treating asthma.⁷ TRA, a selective IL-13 inhibitor, did not show efficacy in phase 3 clinical trials in asthma.⁸ Through multiple studies, DUP has shown effectiveness in the treatment of asthma.^{9,10} DUP is the only medication licensed to treat people with AD and concomitant asthma.¹¹ A *post-hoc* subgroup analysis of DUP use in patients with AD and concomitant asthma demonstrated significant improvements in AD-related outcomes and asthma.¹² In the analysis, the effectiveness of DUP in AD outcomes is equivalent to that of the overall study population and there are no safety differences between AD patients with concomitant asthma and those with AD alone. It would be an interesting issue to explore if early treatment with DUP could prevent subsequent asthma development in children with AD.

Janus kinases (JAK) mediate the activity of many asthma-relevant cytokines. Theoretically and based on animal models they might be used to treat asthma. GDC-0214 and GDC-4379, inhaled small molecule JAK1 inhibitors, demonstrated dose-dependent reductions of fractional exhaled nitric oxide and peripheral biomarkers of inflammation in patients with mild asthma.^{13,14}

JAK1/2 inhibitor BAR demonstrated a promising treatment for severe eosinophilic asthma.¹⁵ To evaluate the impact JAK inhibitors (JAKis) can have on treating asthma, more research must be done.

Allergic rhinitis and chronic rhinosinusitis with sinonasal polyposis

Allergic rhinitis and chronic rhinosinusitis with sinonasal polyposis (CRwSNP) are diseases frequently characterized by type 2 inflammation, with the release of pro-inflammatory cytokines such as IL-4, IL-5, IL-9, and IL-13. 10% of patients with CRwSNP have a diagnosis of non-steroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD).¹⁶ According to the findings of two randomized placebo-controlled phase 3 trials in patients with CRwSNP and NSAID-ERD, DUP improved symptoms, endoscopic and radiologic outcomes, and airway function by suppressing underlying type 2 inflammation.¹⁷ A *post-hoc* subgroup analysis of DUP use in patients with AD and chronic sinonasal conditions demonstrated a significant improvement in AD-related outcomes and sinonasal diseases.¹² The effectiveness and safety of anti-IL13 drugs such as TRA in treating rhinitis are not at this time being studied in randomized controlled trials. Also, there are currently no studies proving the efficacy of JAKi therapy in rhinitis.

Ocular surface diseases

Minor Hanifin and Rajka criteria for AD include keratoconus, recurrent conjunctivitis and anterior subcapsular cataract, underlining the evidence that ocular disease is a component of the AD syndrome. A systematic review revealed that allergic conjunctivitis was the most common subtype in patients with AD, while atopic keratoconjunctivitis and infectious conjunctivitis were substantially less common. Conjunctivitis was prevalent in patients with AD at 31.7%, compared to 13.3% in controls.¹⁸ Blepharitis affected 22.0%, dry eye disease 9.1%, keratitis 1.4%, and kerato-

Table 1. Evidence-based treatment algorithm for moderate-to-severe atopic dermatitis in patients with comorbidities and in special populations.

	Biologics		Small-molecules JAK inhibitors		
	Dupilumab	Tralokinumab	Upadacitinib	Abrocitinib	Baricitinib
Asthma	↑↑	-	-	-	-
Allergic rhinitis and CRwSNP	↑↑	-	-	-	-
Ocular surface disease	↓	-	↑	↑	↑
Herpes simplex virus	↑	↑	↓	↓	
Herpes zoster	↑	↑	↓	↓	↓
HBV	↑	↑	↓	↓	↓
HIV	↑	-	-	-	-
Latent/untreated TB	↑	↑	↓↓	↓↓	↓↓
Arthritis	↓		↑↑		↑↑
Inflammatory bowel disease	↑	↑	↑↑		
Alopecia areata	-	-	-	↑	↑↑
Vitiligo	↓	-	-	-	-
Psoriasis	↓	-	↑	-	-
Solid tumor	↑	↑	↓↓	↓↓	↓↓
Hematologic neoplasm	↓	↓	↓↓	↓↓	↓↓
Pregnancy breastfeeding	-	-	↓↓	↓↓	↓↓
Pediatric patients	↑↑	-	-	-	-
Adolescent patients	↑↑	-	↑↑	-	-
Elderly patients	↑	↑	↓	↓	↓

↑↑, Preferable choice; ↑, Possible choice; -, See the main text for specific recommendation; ↓, Not recommended as first line choice; ↓↓, Contraindicated or not advisable choice. JAK, Janus kinases; CRwSNP, chronic rhinosinusitis with sinonasal polyposis; HBV, hepatitis B virus; HIV, human immunodeficiency virus; TB, tuberculosis.

conus affected less than 1%.¹⁹ Medication-induced ocular surface disease (mOSD) is the term used to characterize patients who have a new onset of OSD or an exacerbation of an existing OSD following the start of a new medication. In AD populations, this is noticeable with IL-4 and/or IL-13 inhibitors.

Although no mOSD-specific predictive factors have been established, higher baseline AD severity and a history of conjunctivitis were linked to an increased incidence of ocular AEs in DUP clinical trials.^{20,21} Clinical trials of DUP for other diseases, such as asthma and CRWSNP, have not revealed this elevated prevalence.²²

According to an analysis of five TRA randomized controlled trials, an increased risk of conjunctivitis was found in both the placebo and treatment groups and it was linked to more severe baseline AD, a history of allergic conjunctivitis or atopic keratoconjunctivitis and a higher number of atopic comorbidities.²³ Most of the reported cases of conjunctivitis were mild-to-moderate in severity, resolved during the clinical trial and did not lead to treatment discontinuation.^{22,23}

The pathophysiological mechanisms of DUP/TRA-induced AEs are not fully understood. According to some studies, by blocking IL-4 and IL-13, these monoclonal antibodies prevent the activation of conjunctival goblet cells, which would result in hypoplasia and a decrease in mucin synthesis, which would have an impact on the mucosal epithelial barrier function.²⁴ A lower incidence of ocular adverse events was observed in the JAKi-treated patients in head-to-head studies comparing ABR and UPA to DUP, in some cases lower than placebo.^{25,26} Randomized clinical trials on BAR showed that the proportion of patients with a conjunctival disorder was lower in the BAR vs. placebo groups.²⁷

Of note, Th2 blockage with IL-4 and IL-13 inhibitors can promote a shift towards the Th1 phenotype, which is associated with atopic keratoconjunctivitis.²⁸ One explanation is that JAKis' more extensive immunomodulatory impact (targeting both Th2 and Th1) may prevent OSD by reducing this Th1 shift.¹¹

Patients with a history of severe OSD should start JAKi therapy rather than biologics to prevent the possibility of severe OSD recurrence. Conjunctivitis incidence during TRA treatment was comparable with placebo and further studies in a real-life setting are needed.

Patients with past and current infections

Infectious complications during biological and small molecule therapies depend on the immune cell or cytokine inhibited. Most infections arise during the first year of biological therapy and the main ones are bacterial infections, mycobacterial and fungal diseases, herpes zoster and hepatitis B virus (HBV) reactivation.²⁹

Herpes simplex virus

AD is associated with an increased risk of herpes virus infections. Eczema herpeticum (EH) is a severe disseminated herpes simplex virus (HSV) infection, reported to occur in approximately 3% of patients with AD,³⁰ and can cause life-threatening complications.³¹ The incidence rates of herpesvirus infection was slightly higher (1%) in the DUP groups than in the placebo groups,³² however, these were not serious and should not influence treatment choices.³³

A meta-analysis of eight randomized controlled trials revealed decreased risks of EH in patients who received DUP compared with placebo.³³ TRA-treated patients had lower rates of HSV infection and EH vs. placebo in ECZTRA 1 and ECZTRA 2 stud-

ies.²³ UPA and ABR showed increases in the overall prevalence of HSV infections compared to placebo in pooled analyses of clinical trials.^{25,34} Incidences of HSV, but not EH, were dose-dependent with ABR.³⁵

HSV infection was reported more frequently for BAR 4 mg compared to BAR 2 mg and placebo. However, HSV incidence in the extended data set was higher in the placebo group suggesting that prolonged treatment with BAR does not result in a continuous increase of HSV incidence. EH infection incidence was higher in the BAR 4 mg group and correlated with AD severity, while there was no increase in HE incidence in the BAR 2 mg group.²⁷

Systemic medication may change the frequency of HSV in AD patients. Patients with a history of recurrent or severe HSV infection should be screened for the virus and physicians should consider prophylactic or prompt antiviral treatment.¹¹ In conclusion, therapy with DUP and TRA may be preferable to JAKis.

Herpes zoster

AD is associated with an increased risk of herpes zoster (HZ).³⁶ Compared to placebo, the rate of HZ was lower in patients receiving DUP.³² The published phase 3 clinical trial data for TRA does not identify HZ as an adverse event.²³

In comparison to placebo, JAKis showed increases in the overall frequency of HZ infections.^{25,35}

In head-to-head studies of DUP vs. ABR and UPA, the reactivations of varicella-zoster virus were numerically higher for patients treated with UPA and ABR than those treated with DUP, all at generally low levels. All HZ events were mild or moderate in severity.^{25,26} More events of HZ were reported in the BAR 2 mg group than placebo or BAR 4 mg groups.²⁷

Therapy with DUP and TRA may be preferable to JAKis in patients who have HZ risk factors. Before beginning systemic treatment with JAKis, the HZ vaccine should be taken into consideration.¹¹ In conclusion, therapy with DUP and TRA may be preferable to JAKis.

Hepatitis B virus

Hepatitis B virus (HBV) reactivation can be a serious complication for patients with chronic or resolved HBV infection when treated with biologics.

Due to the exclusion criteria,³⁷ HBV-positive individuals were not included in DUP clinical studies, and there is no published data indicating that DUP is safe for HBV infection.

Only one case report on two patients with chronic HBV infection in treatment with entecavir and DUP shows no viral reactivation.³⁸ Furthermore, in a prospective report of five patients treated with DUP who were HBV surface antigen positive and did not receive HBV medication no viral reactivation was detected.³⁹

TRA phase 3 clinical studies have not reported any cases of HBV reactivation, potentially reflecting trial exclusion criteria for patients with a history of HBV.¹¹

DUP and TRA specifically inhibit Th2 immune responses while having limited effect on Th1 immune responses.⁴⁰ Given that HBV suppression occurs primarily through a Th1 immune response, DUP and TRA are unlikely to cause HBV reactivation.

There are no published data on HBV-positive patients receiving JAKis for AD. Despite this, cases of HBV reactivation after therapy with JAKis for rheumatoid arthritis are reported in the literature.⁴¹⁻⁴³ JAKi may enhance the risk of viral reactivation according to their mechanism of action on lymphocytes and interferon (IFN) signaling. Before beginning any systemic therapy for AD, patients with HBV infection who have surface antigen positivity should be investigated for concomitant HBV therapy.¹¹ If

HBV therapy cannot be started, therapy with DUP and TRA may be preferable to JAKi.

Human immunodeficiency virus

History of human immunodeficiency virus (HIV) is one of the exclusion criteria for studies of DUP, TRA, UPA, BAR, and ABR.

For these reasons, there are no safety data for these therapies. Several cases of HIV patients treated with DUP are reported in the literature.^{44,45} According to all published cases, DUP is safe in individuals with HIV who have stable CD4 counts and low viral loads.⁴⁶

Tuberculosis

A third of the world's population is exposed to *Mycobacterium tuberculosis* in their lifetime.⁴⁷

Treatment with biological agents is associated with an increased risk of tuberculosis (TB) and this risk is highest with tumor necrosis factor-alpha inhibitors.⁴⁸

Currently, no TB screening is necessary for biologics licensed for AD.⁴⁹ Based on their mode of action, biologics that target the IL-13/IL-4R axis would not disrupt granulomas and cause unregulated TB proliferation.^{48,50} Clinical trials for AD patients often exclude those with a history of TB. JAKi should not be administered to patients with latent TB until the latent TB has been treated.⁵¹⁻⁵³ They might increase the risk of TB infections, through down-regulating Th1 responses and production of IFN- γ involved in protective immunity against *M. tuberculosis*.⁵⁴ Patients with latent TB should not be treated with JAKi until latent TB is treated. In patients with untreated latent TB therapy with DUP and TRA may be preferable to JAKi.

Patients with arthritis and inflammatory bowel diseases

The association of AD with autoimmune disorders has been extensively investigated. A recent meta-analysis demonstrated that AD increases the risk of developing rheumatoid arthritis (RA), ulcerative colitis (UC), and Crohn's disease (CD).⁵⁵ Considering the presence of these comorbidities in patients with AD, the choice of therapy should be carefully evaluated to ensure a safe and potentially pleiotropic treatment option.

Arthritis

Regarding AD and arthritis, the Italian Medicines Agency (AIFA) has approved the use of UPA in patients with RA, psoriatic arthritis (PsA), and ankylosing spondylitis (AS) and approved the use of BAR in patients with RA. An integrated safety analysis of UPA, which included clinical trials involving patients with RA, PsA, AS, and AD, confirmed an acceptable safety profile with no new safety risks. UPA and BAR may represent two suitable options for AD patients with arthritis.^{56,58}

However, there is currently no available data on the effects of TRA and ABR on arthritis. DUP-associated enthesitis and arthritis have been described in literature. In most cases, the symptoms were mild and did not require discontinuation of DUP. However, in cases of moderate-to-severe arthritis, administration of non-steroidal anti-inflammatory drugs or discontinuation of DUP was necessary.⁵⁹⁻⁶⁵ Bostan *et al.* reported a case of reactivation of inflammatory monoarthritis during DUP therapy.⁶⁶

Bridgewood *et al.* conducted a pharmacovigilance analysis using VigiBase and observed an association between DUP and

seronegative arthritis and enthesitis/enthesopathy. The proposed pathogenetic mechanism involved the induction of IL-17-driven inflammation secondary to the downregulation of the IL-4/IL-13 axis.^{67,68}

Inflammatory bowel diseases

There are concerns regarding the potential onset or exacerbation of inflammatory bowel disease (IBD) with IL-4/IL-13 blockade and limited data exist on the use of DUP in patients with IBD.^{69,70} Spencer *et al.* conducted a study involving seventeen IBD patients who were receiving DUP for severe AD, as well as AD or psoriasisform dermatitis induced by anti-TNF therapy for IBD management. Among these patients, eight received a combination of biologics, including DUP and anti-TNF, ustekinumab, or vedolizumab. All patients showed a positive response to DUP for AD, and no adverse events were reported, including no increase in IBD activity.⁷¹

Studies have presented contrasting results regarding the effects of IL-13 cytokine in UC and CD.⁷² TRA has been evaluated in moderate-to-severe UC, but it did not significantly improve clinical response compared to placebo. However, TRA was associated with a higher remission rate, suggesting potential benefits for certain UC patients.⁷³

Clinical trials have demonstrated the efficacy and tolerability of UPA in IBD patients, leading to its approval by AIFA for the induction and maintenance therapy of moderate-to-severe UC and CD.⁷³⁻⁸²

Grieco *et al.* reported a case of a patient with overlapping AD and UC who was successfully treated for both conditions with UPA 15 mg.⁷⁷ UPA may hold promise as a treatment option for patients with concurrent AD and IBD.

Currently, there is no available data on the effect of ABR and BAR on patients with IBD. Further research is needed to assess their potential impact on this patient population.

Patients with concomitant autoimmune or inflammatory skin diseases

Patients with AD are at higher risk of developing multiple autoimmune skin diseases, including alopecia areata and vitiligo.⁵⁵ Moreover, patients with overlapping AD and psoriasis have been increasingly reported and this association represents a therapeutic challenge.⁸³

Alopecia areata

In patients with concomitant AD and alopecia areata (AA), DUP demonstrated controversial effects.⁸⁴ Several authors reported AA onset or worsening during DUP therapy for AD.^{82,85-94} However, there have also been observations of hair regrowth in both adult and pediatric patients receiving DUP.⁹⁵⁻¹⁰⁰ Recent evidence suggests that the Th2 immune axis may play a role in the pathogenesis of AA.¹⁰¹ Patients with more severe and long-standing histories of AD and atopic comorbidities have shown greater improvement in AA with DUP treatment.^{102,103} A phase 2 randomized clinical trial (NCT03359356) investigating DUP for AA patients demonstrated a higher response in atopic patients with baseline serum IgE levels ≥ 200 IU/ml.¹⁰⁴

Conversely, patients with a shorter duration and later onset of AD, as well as those without atopic comorbidities, may exhibit less prominent Th2 skewing. The downregulation of Th2 immune response following DUP use in these individuals may lead to an

abrupt skewing towards Th1, potentially promoting the pathogenesis of AA and subsequent hair loss.¹⁰³

Baricitinib has recently been approved by the AIFA for the treatment of AA with the Severity of Alopecia Tool (SALT) score >50,¹⁰⁵ based on the results of two randomized, placebo-controlled Phase 3 trials (BRAVE-AA1 and BRAVE-AA2).¹⁰⁶ BRAVE-AA1 trial, focusing on patients with severe AA, showed that at week 36, the percentage of patients achieving a SALT score of 20 or less was 38.8% for 4 mg BAR, 22.8% for 2 mg BAR, and 6.2% for placebo. Similarly, in BRAVE-AA2, the corresponding figures were 35.9%, 19.4%, and 3.3%, respectively. Although there is currently no *post hoc* analysis on trials involving patients with both AA and AD, such an analysis could provide valuable insights into the efficacy of BAR as a simultaneous treatment for both conditions. A case series involving three adult patients affected by both AA and AD reported the efficacy of BAR in leading to clinical improvement of diseases.¹⁰⁷ A single patient case report highlighted the efficacy of switching from 2 mg to 4 mg of daily BAR in improving AD signs in a 45-year-old male treated for his patchy AA.¹⁰⁸

A randomized, double-blind, placebo-controlled pilot study (NCT02684097) was started to evaluate the efficacy of TRA in AA. The study enrolled a total of 30 participants with moderate to severe AA, with 50% expected to have concomitant AA and AD. The TRA group received subcutaneous injections every two weeks for 24 weeks, while the placebo group received saline injections as a control. Of the enrolled participants, 2 in the TRA group and 1 in the placebo group completed the study, while the remaining participants discontinued due to lack of efficacy.¹⁰⁹

The use of UPA in the treatment of AA and related conditions has shown promising results, as highlighted in recent studies. In a multicenter retrospective study by Chiricozzi *et al.*,¹¹⁰ UPA demonstrated beneficial effects on AA associated with AD, with a significant reduction in mean baseline SALT score from 95.1 ± 9.6 to 77.6 ± 28.2 after 4 weeks of treatment. The study also reported incremental decreases in SALT score over time, with a higher percentage of patients achieving SALT50, SALT75, SALT90, and SALT100 responses. Previously, Cantelli *et al.* reported the case of a 24-year-old patient with a history of AD and severe AA who was treated with UPA after the failure of previous therapies. After 3 months of UPA therapy, significant clinical improvement was observed in both AD and AA, with regrowing hair all over the scalp and no signs of disease activity.¹¹¹ More data regarding the pediatric populations are coming from case series. The study by Yu and Ren reported a case of successful treatment with UPA in a child with alopecia universalis (AU) and mild AD (EASI 2.5).¹¹² The patient experienced substantial hair regrowth after 4 weeks of UPA treatment, with a marked improvement in the SALT score from 100% at baseline to 0% at week 12. Similarly, Bourkas and Sibbald reported a pediatric patient with AA and severe AD achieving a reduction in the SALT score from 95.1 ± 9.6 at baseline to 77.6 ± 28.2 at week 4,¹¹³ indicating a positive response to UPA therapy. The role of ABR in the treatment of AA has been investigated only in case reports up to now. In the study by Bennett *et al.*,¹¹⁴ a 33-year-old male with severe AD and chronic universal AA achieved complete remission of AA with ABR. Similarly, Zhao *et al.*¹¹⁵ reported a case of a 14-year-old girl with AD and AU who experienced thick regrowth of terminal hairs on various body parts after ABR treatment. Huang *et al.*¹¹⁶ presented a case of refractory AA in an 11-year-old boy, where ABR led to significant hair regrowth after 4 months of therapy. These case reports provide valuable insights into the potential efficacy of ABR for the treatment of AA, including in pediatric patients.

Vitiligo

Biologics and vitiligo: dupilumab and tralokinumab

Vitiligo onset or exacerbation represents a rare cutaneous adverse event reported during DUP therapy. Non-segmental vitiligo with facial involvement represented the most common type. DUP-associated vitiligo showed a good prognosis in most of the cases with response to topical treatments or narrow-band UVB phototherapy. However, DUP discontinuation was necessary in three patients with non-responsive and rapidly worsening vitiligo.¹¹⁷⁻¹²⁰ Currently, no data on the association between TRA administration and vitiligo are available.

Janus Kinases inhibitors and vitiligo: upadacitinib, baricitinib, and abrocitinib

The JAK/STAT signaling pathway is involved in vitiligo pathogenesis. Ruxolitinib and tofacitinib lead to vitiligo improvement in most cases. However, less is known about the effect of other types of JAKi. Pan *et al.* reported a 16-year-old boy with both AD and vitiligo was successfully treated for both conditions with UPA 15 mg.¹²¹ Preliminary data showed that BAR was effective in vitiligo treatment.¹²²⁻¹²⁴ No data about ABR effects on patients affected by vitiligo are available.

Psoriasis

DUP-associated psoriasis and psoriasiform manifestations include plaque, guttate, erythrodermic, pustular, and reverse psoriasis.^{85,125-141} DUP downregulates the Th2 pathway and might lead to Th17 subsets shift and the activation of IL-23/Th17 axis in psoriasiform lesions.^{142,143} In patients affected by psoriatic arthritis UPA 15 mg provided a positive response on plaque psoriasis in 52.3% of cases.¹⁴⁴ Gargiulo *et al.* reported four patients with concomitant psoriasis and AD successfully treated with UPA for both conditions.¹⁴⁵ Moreover UPA demonstrated effectiveness in a 58-year-old female with psoriasiform dermatitis induced by DUP.¹⁴⁶

However, the phenotypic switch from AD to psoriasis during treatment with UPA was recently described.¹⁴⁷ In a randomized phase 2b trial of BAR a positive clinical response was documented in patients with moderate-to-severe psoriasis.¹⁴⁸ Moreover, BAR was successfully administered in AR patients with psoriasis induced by bDMARDs.¹⁴⁹ Currently, no data on TRA and ABR in psoriatic patients are available.

Patients with neoplasm history

The associations between AD and cancer are not yet well understood. Two cohort studies from England and Denmark did not find evidence of an association between AD and most cancers, except for lymphomas.^{150,151} AD patients with long-term severe disease have been observed to have a higher risk of developing lymphoma in adulthood 1,150, and pediatric cases have also been reported.¹⁵²

Dupilumab and tralokinumab in patients with neoplasm history

Patients with a history of malignancy are generally excluded from biologics clinical trials. However, real-life studies have shown that DUP is not associated with an increased risk of malignancy and can be considered a safe option for patients with a history of solid neoplasms.¹⁵³⁻¹⁵⁶

The relationship between DUP and the risk of developing lymphomas, particularly cutaneous T-cell lymphomas (CTCL), is con-

troversial. While Th2-cytokines, including IL-4 and IL-13, are overexpressed in advanced CTCL,¹⁵⁷ the use of DUP has been associated with the onset or progression of CTCL in several cases.¹⁵⁸⁻¹⁶⁴ Furthermore, other types of lymphomas such as anaplastic large-cell lymphoma, cytotoxic T-cell lymphoma, angioimmunoblastic T-cell lymphoma, and Hodgkin lymphoma have been reported during DUP therapy.¹⁶⁵⁻¹⁶⁹ The current available published data provide reassurance regarding the use of DUP in patients with a history of solid tumors, but caution must be exercised in the case of hematological malignancies.

There is a lack of real-life studies examining the risk of cancer in patients treated with TRA. In the ECZTEND safety analysis, the occurrence of tumors diagnosed after randomization was very rare (0.8%).¹⁷⁰

Despite the limited evidence, biologics, including DUP and TRA, are considered the preferred treatment options for patients with AD and a history of cancer based on their mechanism of action and expert opinion.¹¹

A case-by-case approach and multidisciplinary discussion involving oncologists and hematologists are recommended to guide treatment decisions in these patients.

Upadacitinib, abrocitinib, and baricitinib in patients with neoplasm history

Patients with active cancer or a history of several cancers are generally not suitable candidates for treatment with JAKis.¹⁷¹

EMA has formulated some measures to minimize the risk of serious side effects, and JAKis should be considered in patients with malignancy risk factors, only if anti-IL therapies are no suitable options.¹⁷² It is important to note that most of the safety concerns regarding JAKis, particularly tofacitinib, have emerged from post-marketing studies conducted in RA patients.¹⁷³ A study by Burmester *et al.* evaluated the safety profile of UPA in a large cohort of 6,991 patients, including 2,693 patients with AD. In AD patients, the rates of malignancy were higher with UPA 30 mg compared to UPA 15 mg. It is worth noting that four out of the nine malignancies observed with UPA 30 mg occurred within 6 months after starting the treatment. Overall, this analysis confirmed the known safety profile of UPA without identifying any new safety risks.⁵⁶ Regarding ABR treatment, cancer events reported during phase 2 and 3 studies were rare, with cases of non-melanoma skin cancer (NMSC) and lymphoma being reported.³⁵ Malignancies reported during BAR treatment were rare, and included NMSC, lymphomas, breast cancer, and papillary thyroid cancer.²⁷

Caution should be exercised when considering JAKis in patients with a history of cancer or active cancer.

Patients with childbearing and breastfeeding potential

AD is the most frequent skin disease during the first and second trimesters of pregnancy. The onset or the recurrence of AD during gestation is called “atopic eruption of pregnancy” and should be distinguished from other pruritic eruptions.¹⁷⁴ JAKis, including UPA, BAR and ABR, are contraindicated in pregnancy and breastfeeding based on animal studies that showed teratogenic effects.⁵¹⁻⁵³ Therefore, women of childbearing potential must be advised to use effective contraception during treatment and for four weeks following the last dose of JAKi. No data are available on the excretion of JAKis in human milk, but this is likely due to

their pharmacokinetics. Regarding DUP, it appears to be safe for use during pregnancy. An analysis of the VigiBase pharmacovigilance database showed that DUP use was not associated with an increased risk of abortion, pre-eclampsia, or pre-term premature rupture of membranes. The only event with an odds ratio greater than 1 was the risk of ectopic pregnancy, although only one case was reported.¹⁷⁵

Escolà *et al.* published a case series of 13 women who were exposed to DUP during pregnancy and breastfeeding with no reported side effects and excellent maternal-fetal outcomes.¹⁷⁶

Moreover, DUP proved to be effective and safe during pregnancy in a woman affected by AD, hyper IgE syndrome, and ulcerative colitis.¹⁷⁷

However, it is important to note that safety data on biologics, including DUP and TRA, during pregnancy are still limited and continuous surveillance is needed.¹⁷⁸

Pediatric and adolescent patients

AD commonly develops in early childhood and affects up to 20% of children. AD can lead to anxiety, depression, and reduced quality of life, impacting social life and school performance.

Dupilumab

DUP has shown significant improvement in AD signs, symptoms, and quality of life in adolescents and children with moderate to severe AD, with an acceptable safety profile.

A phase 3 clinical trial (NCT03054428) demonstrated the efficacy and safety of DUP in adolescents aged 12-17 years who had inadequate control with topical medications or for whom topical therapy was not advisable. The every-2-week regimen was more effective than the every-4-week regimen. Adverse events such as conjunctivitis, injection-site reactions, and non-herpetic skin infections were observed, but were generally of mild-to-moderate severity and resolved during the trial.¹⁷⁹

DUP in combination with topical corticosteroids (TCS) also showed efficacy and safety in a phase 3 study (NCT03345914) on children aged 6-11 years with severe AD that was inadequately controlled with topical therapies. Injection-site reactions and conjunctivitis were the most notable adverse events during DUP treatment, but they were generally mild-to-moderate in severity and resolved during the trial.¹⁸⁰

A recent phase 3 study (NCT03346434) evaluated DUP in combination with low-potency TCS in children with moderate-to-severe AD aged from six months to less than six years, showing efficacy and an acceptable safety profile similar to older children, adolescents, and adults.¹⁷⁹

In a real-life Italian study on 139 adolescents with moderate-to-severe AD, DUP confirmed its efficacy and safety profile.¹⁸¹ In Italy, DUP is approved and reimbursed in adolescent (12-17 years) and pediatric (6-11 years) patients.

Tralokinumab

TRA has demonstrated effectiveness in the phase 3 ECZTRA 6 trial on adolescents aged 12-17 years with moderate-to-severe AD. Most adverse events were non-serious and mild or moderate in severity, including conjunctivitis, which had a low incidence and similar occurrence between TRA and placebo arms at week 16. No increases in conjunctivitis were observed up to 52 weeks of treatment. Moreover, in the TRA 300 mg arm there were no cases of conjunctivitis, and fewer AD exacerbation compared to the TRA 150 mg arm.¹⁸² Currently, in Italy, TRA is still not yet

approved for AD in adolescents.

Upadacitinib

UPA has demonstrated efficacy on adolescents aged 12-17 years in three phase 3 clinical trials: Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and AD Up (NCT03568318). In all these trials the benefit-risk profile was favorable, and the most common adverse events were acne, headache, upper respiratory tract infection, creatine phosphokinase level elevations, and nasopharyngitis.¹⁸³⁻¹⁸⁵ These data were confirmed by De Greef *et al.* in a case series including seven adolescent patients.¹⁸⁶ In Italy, UPA is approved but not yet reimbursed (as of July 2023) for AD in adolescents aged 12-17 years.

Abrocitinib

In JADE MONO-1 (NCT03349060) and JADE MONO-2 (NCT0357587) phase 3 clinical trials, ABR 100 mg and 200 mg monotherapy were administered to adolescent and adult patients with moderate-to-severe AD.^{34,187} In JADE TEEN phase 3 study (NCT03796676), ABR 100 mg e ABR 200 mg in combination with topical therapy were administered to adolescent patients.¹⁸⁸

In all the studies both ABR doses resulted in significant improvement in AD signs and symptoms compared with placebo in adolescents. Most adverse events were mild and infrequently required interruption or permanent discontinuation of ABR therapy. The most common adverse events included nausea, nasopharyngitis, headache, upper respiratory tract infection and acne.^{35,188} Currently, in Italy, ABR is not yet approved for the treatment of AD in adolescents.

Baricitinib

A phase 3 randomized controlled trial (BREEZE-AD PEDS) evaluated the effectiveness of BAR in combination with TCS for treating moderate-to-severe AD in 438 children aged 2 to <18 years. Participants were randomly assigned to receive placebo or daily doses of BAR (1 mg, 2 mg, or 4 mg) for 16 weeks. The primary endpoint, defined as achieving a ≥ 2 -point improvement in the investigator global assessment with a final score of 0/1 at week 16, was met by 16.4%, 18.2%, and 25.8% of patients in the placebo, BAR 2 mg, and BAR 4 mg groups, respectively. Compared to placebo, the BAR 4 mg group demonstrated statistically significant improvements in secondary endpoints, including EASI-75, EASI-90, mean change in EASI score, SCORAD 75, and Itch NRS with 4-point improvement for patients aged ≥ 10 years.¹⁸⁹

Elderly patients

Based on the location and evolution of eczematous lesions at different ages, three groups of AD patients have been well-established: infantile-type, childhood-type and adolescent and adult-type. Elderly-type AD has recently been considered a fourth separate group.¹⁹⁰ Studies estimate that 2 to 7% of the elderly population (>65 years) is affected by AD.¹⁹¹ Elderly patients need more consideration in the therapeutic choice. A complete clinical history must include a history of cancer, comorbidities, comedication, cognitive decline and ability to self-administer medications. Clinical evidence about the effectiveness and safety of biologics and small molecules in the elderly population is still limited. Clinical trials usually exclude older people due to upper age restrictions or exclusion criteria for common comorbidities.¹⁹²

To date, seven trials for DUP did not have explicit upper age

limits, although only 4% of participants were over age 65.¹⁹² Four retrospective studies on the treatment of AD in patients aged ≥ 65 years on DUP demonstrated similar efficacy to younger adults.¹⁹³⁻¹⁹⁵ One of these studies showed that older people had a higher incidence of adverse events: injection-site reactions and conjunctivitis being the most common.¹⁹⁴

In TRA studies there was no safety or efficacy difference between the older and younger cohorts, with only 4.8% of the patients being over 65.¹⁹⁶ Currently, there is no specific data available for the use of TRA in the real-world setting in the elderly. However, we would assume that TRA safety and effectiveness profile in the elderly would be comparable to DUP due to a similar mechanism of action.

There are limited data in the literature on the use of JAKis in the elderly population, especially in patients over 75 years of age. According to the prescribing information for JAKis, older people may carry higher risks of adverse events compared with younger adult patients.⁵¹⁻⁵³ Before starting therapy with JAK inhibitors, it is currently recommended to: i) consider general risk factors for cancer (age >65 and smoking) and to explore any history of cancer; ii) assess risk factors for cardiovascular and thromboembolic events, and rule out any history of these events; iii) evaluate the serum lipid profile and pay attention to dyslipidemia. Clinical trials on UPA treatment in moderate-to-severe AD included patients aged 12 to 75 years. Data from AD Up, Measure Up 1, and Measure Up 2 trials showed an exposure-adjusted rate of AEs higher in patients ≥ 65 years of age receiving UPA 30 mg compared to patients ≥ 65 years of age receiving UPA 15 mg and patients <65 years of age receiving either UPA 15 mg or 30 mg.¹⁹⁷

Simpson *et al.* published an integrated safety analysis of ABR for the treatment of moderate-to-severe AD. Adults over 65 years receiving ABR were 5.1%. A multivariate analysis found that age ≥ 65 years was associated with a higher risk of herpes zoster. Malignancies cases occurred in 71.4% of cases in patients ≥ 60 years old. Three patients aged ≥ 60 years old experienced a major adverse cardiovascular event, including two events of myocardial infarction and one event of sudden death.³⁵ More data are needed on BAR safety in elderly patients with AD.¹⁹⁸

We suggest that the first-choice therapy should be biologics because have the most data supporting its use in elderly patients, in particular on DUP use.

Conclusions

Treatment selection for patients with comorbidities and special populations affected by moderate to severe AD is complex, and the purpose of this review is to provide an algorithm for dermatologists to guide the choice of biologics and small molecules. Such an algorithm may undergo changes once new evidence becomes available.

References

1. Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. *Am J Clin Dermatol* 2018;19:821-38.
2. Eichenfield LF, Hanifin JM, Beck LA, et al. Atopic dermatitis and asthma: parallels in the evolution of treatment. *Pediatrics* 2003;111:608-16.
3. Ali FR. Does this patient have atopic asthma? *Clin Med Lond Engl* 2011;11:376-80.

4. Weinmayr G, Weiland SK, Björkstén B, et al. Atopic sensitization and the international variation of asthma symptom prevalence in children. *Am J Respir Crit Care Med* 2007;176:565-74.
5. Pyun BY. Natural history and risk factors of atopic dermatitis in children. *Allergy Asthma Immunol Res* 2015;7:101-5.
6. Saco T, Ugalde IC, Cardet JC, Casale TB. Strategies for choosing a biologic for your patient with allergy or asthma. *Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol* 2021;127:627-37.
7. van de Veen W, Akdis M. The use of biologics for immune modulation in allergic disease. *J Clin Invest* 129:1452-62.
8. Panettieri RA, Sjöbring U, Péterffy A, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. *Lancet Respir Med* 2018;6:511-25.
9. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. *N Engl J Med*. 2018;378:2486-96.
10. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *N Engl J Med* 2018;378:2475-85.
11. Adam DN, Gooderham MJ, Beecker JR, et al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. *J Eur Acad Dermatol Venereol* 2023;37:1135-48.
12. Boguniewicz M, Beck LA, Sher L, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. *J Allergy Clin Immunol Pract* 2021;9:1212-1223.e6.
13. Braithwaite IE, Cai F, Tom JA, et al. Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: a randomized, controlled, proof-of-activity trial. *J Allergy Clin Immunol* 2021;148:783-9.
14. Chen H, Kunder R, Zou Y, et al. Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation. *Pulm Pharmacol Ther* 2022;75:102133.
15. Luschnig P, Kienzl M, Roula D, et al. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia. *Biochem Pharmacol* 2021;192:114690.
16. Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. *J Allergy Clin Immunol* 2015;135:676-681.e1.
17. Mullol J, Laidlaw TM, Bachert C, et al. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials. *Allergy* 2022;77:1231-44.
18. Ravn NH, Ahmadzay ZF, Christensen TA, et al. Bidirectional association between atopic dermatitis, conjunctivitis, and other ocular surface diseases: a systematic review and meta-analysis. *J Am Acad Dermatol* 2021;85:453-61.
19. Thyssen JP, Halling AS, Schmid-Grendelmeier P, et al. Comorbidities of atopic dermatitis-what does the evidence say? *J Allergy Clin Immunol* 2023;151:1155-62.
20. Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. *Br J Dermatol* 2019;181:459-73.
21. Beck KM, Seitzman GD, Yang EJ, et al. Ocular co-morbidities of atopic dermatitis. part i: associated ocular diseases. *Am J Clin Dermatol* 2019;20:797-805.
22. Thaçi D, Simpson LE, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). *J Dermatol Sci* 2019;94:266-75.
23. Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). *Br J Dermatol*. 2021;184:437-49.
24. Bakker DS, Ariens LFM, van Luijk C, et al. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. *Br J Dermatol* 2019;180:1248-9.
25. Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. *JAMA Dermatol* 2021;157:1047-55.
26. Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. *N Engl J Med* 2021;384:1101-12.
27. Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. *J Eur Acad Dermatol Venereol* 2021;35:476-85.
28. Utine CA, Li G, Asbell P, et al. Ocular surface disease associated with dupilumab treatment for atopic diseases. *Ocul Surf* 2021;19:151-6.
29. Lortholary O, Fernandez-Ruiz M, Baddley JW, et al. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. *Ann Rheum Dis* 2020;79:1532-43.
30. Leung DYM. Why is eczema herpeticum unexpectedly rare? *Antiviral Res* 2013;98:153-7.
31. Traidl S, Roesner L, Zeitvogel J, Werfel T. Eczema herpeticum in atopic dermatitis. *Allergy* 2021;76:3017-27.
32. Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. *Am J Clin Dermatol* 2019;20:443-56.
33. Fleming P, Drucker AM. Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials. *J Am Acad Dermatol* 2018;78:62-69.e1.
34. Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Lond Engl* 2020;396:255-66.
35. Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. *Am J Clin Dermatol* 2021;22:693-707.
36. Narla S, Silverberg JI. Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults. *Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol* 2018;120:66-72.e11.
37. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. *Lancet Lond Engl* 2017;389:2287-303.
38. Ly K, Smith MP, Thibodeaux Q, et al. Dupilumab in patients with chronic hepatitis B on concomitant entecavir. *JAAD Case Rep* 2019;5:624-6.

39. Matsutani M, Imai Y, Nakatani-Kusakabe M, et al. Dupilumab in atopic dermatitis patients with chronic hepatitis B. *J Cutan Immunol Allergy* 2022;5:65-6.
40. Imai Y, Kusakabe M, Nagai M, et al. Dupilumab effects on innate lymphoid cell and helper T cell populations in patients with atopic dermatitis. *JID Innov Skin Sci Mol Popul Health* 2021;1:100003.
41. Wang ST, Tseng CW, Hsu CW, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib. *Int J Rheum Dis* 2021;24:1362-9.
42. Zhang Z, Deng W, Wu Q, Sun L. Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. *Immunotherapy* 2019;11:321-33.
43. Harigai M, Winthrop K, Takeuchi T, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. *RMD Open* 2020;6:e001095.
44. Avallone G, Trunfio M, Giura MT, et al. Dupilumab in HIV-positive patients with atopic dermatitis: a long-term follow-up patient and a literature review. *Dermatol Online J* 2021;27.
45. Alawadhi A, Karibayeva D, Gottlieb AB. Dupilumab in HIV-positive patients: a case series report of 4 patients. *JAAD Case Rep* 2020;6:1356-9.
46. Edmonds N, Zhao P, Flowers RH. The use of dupilumab in patients with HIV. *Int J STD AIDS* 2022;33:1165-73.
47. Yasui K. Immunity against *Mycobacterium tuberculosis* and the risk of biologic anti-TNF- α reagents. *Pediatr Rheumatol Online J* 2014;12:45.
48. Godfrey MS, Friedman LN. Tuberculosis and biologic therapies: anti-tumor necrosis factor- α and beyond. *Clin Chest Med* 2019;40:721-39.
49. Sanofi-aventis Canada Inc. Dupixent (Dupilumab) injection. Product monograph. 2022. Available from: https://pdf.hres.ca/dpd_pm/00065186.PDF (accessed on 16th June 2022).
50. Rook GAW. Th2 cytokines in susceptibility to tuberculosis. *Curr Mol Med* 2007;7:327-37.
51. AbbVie Corporation. Rinvoq (Upadacitinib) tablets. Product monograph. 2022. Available from: https://pdf.hres.ca/dpd_pm/00066875.PDF (accessed on 16th June 2022).
52. Pfizer Labs. Cibinqo (Abrocitinib) Tablets. Prescribing information. New York, NY: Pfizer Labs; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213871s000lbl.pdf (accessed on 17th June 2022).
53. Lilly. Baricitinib (Olumiant) tablets. Product monograph. 2022. Available from: <https://pi.lilly.com/ca/olumiant-ca-pm.pdf>
54. Coltro G, Vannucchi AM. The safety of JAK kinase inhibitors for the treatment of myelofibrosis. *Expert Opin Drug Saf* 2021;20:139-54.
55. Lu Z, Zeng N, Cheng Y, et al. Atopic dermatitis and risk of autoimmune diseases: a systematic review and meta-analysis. *Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol* 2021;17:96.
56. Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. *RMD Open* 2023;9:e002735.
57. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis* 2023;82:3-18.
58. Eli Lilly and Company. A randomized, controlled pragmatic phase 3b/4 study of baricitinib in patients with rheumatoid arthritis. 2023. Report No.: NCT04086745. Available from: <https://clinicaltrials.gov/study/NCT04086745> (accessed on 24th July 2023)
59. Nathan J, Hughes C, Patel S, et al. Ab0573 dupilumab-induced enthesitis/arthritis in patients with atopic dermatitis: a retrospective observational study. *Ann Rheum Dis* 2021;80:1323-4.
60. Willsmore ZN, Woolf RT, Hughes C, et al. Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. *Br J Dermatol* 2019;181:1068-70.
61. de Wijs LEM, van der Waa JD, de Jong PHP, Hijnen DJ. Acute arthritis and arthralgia as an adverse drug reaction to dupilumab. *Clin Exp Dermatol* 2020;45:262-3.
62. Komaki R, Miyagaki T, Nakajima K, et al. Arthritis and enthesitis during dupilumab therapy completely remitted by celecoxib. *J Dermatol* 2021;48:e279-80.
63. Ishibashi M, Honda T, Tabuchi Y, Kabashima K. Polyenthesitis during treatment with dupilumab for atopic dermatitis. *J Eur Acad Dermatol Venereol* 2020;34:e319-21.
64. Chrétien B, Dolladille C, Alexandre J, et al. Dupilumab-associated arthralgia: an observational retrospective study in VigiBase®. *Br J Dermatol* 2021;185:464-5.
65. Hughes CD, Nathan J, Mathew L, et al. Characterization of a musculoskeletal syndrome of enthesitis and arthritis in patients with atopic dermatitis treated with dupilumab, an IL-4/13 inhibitor. *Arthritis Rheumatol Hoboken NJ* 2023;75:1793-7.
66. Bostan E, Gülseren D, Özsoy Z, Ergen FB. Reactivation of inflammatory monoarthritis during dupilumab treatment used for prurigo nodularis. *Arch Rheumatol* 2022;37:148-9.
67. Bridgewood C, Wittmann M, Macleod T, et al. T helper 2 IL-4/IL-13 dual blockade with dupilumab is linked to some emergent T Helper 17-type diseases, including seronegative arthritis and enthesitis/enthesopathy, but not to humoral autoimmune diseases. *J Invest Dermatol* 2022;142:2660-7.
68. Bridgewood C, Sharif K, Freeston J, et al. Regulation of enthesal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy. *Rheumatol Oxf Engl* 2021;60:2461-6.
69. Shimodaira Y, Takahashi S, Iijima K. Anti-IL-4R α monoclonal antibody dupilumab mimics ulcerative colitis: a case report. *BMC Gastroenterol* 2021;21:207.
70. Pagan AD, Ghalili S, Cices A, et al. Atopic dermatitis induced during anti-TNF- α therapy for inflammatory bowel disease: Potential for Th2 inhibition with dupilumab. *J Allergy Clin Immunol Pract* 2023;11:2235-2238.e1.
71. Spencer EA, Dolinger MT, Dubinsky MC. A single-center experience with dupilumab for atopic or psoriasiform dermatitis in patients with inflammatory bowel disease. *Dig Dis Sci* 2023;68:1121-4.
72. Giuffrida P, Caprioli F, Facciotti F, Di Sabatino A. The role of interleukin-13 in chronic inflammatory intestinal disorders. *Autoimmun Rev* 2019;18:549-55.
73. Danese S, Rudziński J, Brandt W, et al. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. *Gut* 2015;64:243-9.
74. Sandborn WJ, Feagan BG, Loftus EV, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with crohn's disease. *Gastroenterology* 2020;158:2123-2138.e8.
75. Ghosh S, Sanchez Gonzalez Y, et al. Upadacitinib treatment improves symptoms of bowel urgency and abdominal pain, and correlates with quality of life improvements in patients with moderate to severe ulcerative colitis. *J Crohns Colitis* 2021;15:2022-30.
76. D'Haens G, Panés J, Louis E, et al. Upadacitinib was effica-

- cious and well-tolerated over 30 months in patients with Crohn's disease in the CELEST extension study. *Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc* 2022;20:2337-2346.e3.
77. Grieco T, Caviglia M, Cusano G, et al. Atopic dermatitis and ulcerative colitis successfully treated with upadacitinib. *Medicina (Mex)* 2023;59:542.
 78. Friedberg S, Choi D, Hunold T, et al. Upadacitinib is effective and safe in both ulcerative colitis and Crohn's disease: prospective real-world experience. *Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc* 2023;21:1913-1923.e2.
 79. Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis. *Gut* 2023;72:264-74.
 80. Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus Kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. *Gastroenterology* 2020;158:1554-1573.e12.
 81. Loftus EV, Panés J, Lacerda AP, et al. Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. *N Engl J Med* 2023;388:1966-80.
 82. Chugh R, Braga-Neto MB, Fredrick TW, et al. Multicentre real-world experience of upadacitinib in the treatment of Crohn's disease. *J Crohns Colitis* 2023;17:504-12.
 83. Tsai YC, Tsai TF. Overlapping features of psoriasis and atopic dermatitis: from genetics to immunopathogenesis to phenotypes. *Int J Mol Sci* 2022;23:5518.
 84. Patruno C, Napolitano M, Ferrillo M, Fabbrocini G. Dupilumab and alopecia: a Janus effect. *Dermatol Ther* 2019;32:e13023.
 85. Beaziz J, Bouaziz JD, Jachiet M, et al. Dupilumab-induced psoriasis and alopecia areata: case report and review of the literature. *Ann Dermatol Venereol* 2021;148:198-201.
 86. Maiolini VM, Sousa NA, Marsillac PF de, Bressan AL. Alopecia areata-like and psoriasis after dupilumab use for atopic dermatitis. *An Bras Dermatol* 2021;96:634-6.
 87. Chung J, Slaughter CL, Simpson EL. Alopecia areata in 2 patients treated with dupilumab: new onset and worsening. *JAAD Case Rep* 2019;5:643-5.
 88. Kulkarni M, Rohan CA, Morris D, Travers JB. Resolution of dupilumab-associated alopecia areata with dosage modification. *JAAD Case Rep* 2022;22:85-8.
 89. Yazdanyar S, Jemec GBE. Alopecia areata after treatment with dupilumab. *Dermat Contact Atopic Occup Drug* 2019;30:175-6.
 90. Carnicle JM, Hendricks AJ, Shi VY. Reactivation of alopecia areata after dupilumab therapy for atopic dermatitis. *Dermat Contact Atopic Occup Drug* 2021;32:e80-2.
 91. Yamane S, Nakagawa Y, Inui S, Fujimoto M. Development of alopecia areata-like reactions in a patient treated with dupilumab. *Allergol Int Off J Jpn Soc Allergol* 2022;71:420-2.
 92. Mitchell K, Levitt J. Alopecia areata after dupilumab for atopic dermatitis. *JAAD Case Rep* 2018;4:143-4.
 93. Sachdeva M, Witol A, Mufti A, et al. Alopecia areata related paradoxical reactions in patients on dupilumab therapy: a systematic review. *J Cutan Med Surg* 2021;25:451-2.
 94. Jin P, Wei L, Zhang Q, et al. Dupilumab for alopecia areata treatment: A double-edged sword? *J Cosmet Dermatol* 2022;21:5546-8.
 95. Bur D, Kim K, Rogge M. Dupilumab induced hair regrowth in alopecia totalis. *J Drugs Dermatol JDD* 2023;22:410-2.
 96. Gruenstein D, Malik K, Levitt J. Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab. *JAAD Case Rep* 2020;6:1286-7.
 97. McKenzie PL, Castelo-Soccio L. Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis. *J Am Acad Dermatol* 2021;84:1691-4.
 98. Alotaibi L, Alfawzan A, Alharthi R, Al Sheikh A. Improvement of atopic dermatitis and alopecia universalis with dupilumab. *Dermatol Rep* 2022;14:9359.
 99. Cho SK, Craiglow BG. Dupilumab for the treatment of alopecia areata in children with atopic dermatitis. *JAAD Case Rep* 2021;16:82-5.
 100. Ludriksone L, Elsner P, Schliemann S. Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients. *J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG* 2019;17:1278-80.
 101. Renert-Yuval Y, Pavel AB, Del Duca E, et al. Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata. *Allergy* 2023;78:1047-59.
 102. Magdaleno-Tapiál J, Valenzuela-Oñate C, García-Legaz-Martínez M, et al. Improvement of alopecia areata with Dupilumab in a patient with severe atopic dermatitis and review the literature. *Australas J Dermatol* 2020;61:e223-5.
 103. Marks DH, Mesinkovska N, Senna MM. Cause or cure? Review of dupilumab and alopecia areata. *J Am Acad Dermatol* 2023;88:651-3.
 104. Guttman-Yassky E, Renert-Yuval Y, Bares J, et al. Phase 2a randomized clinical trial of dupilumab (anti-IL-4R α) for alopecia areata patients. *Allergy* 2022;77:897-906.
 105. Gazzetta Ufficiale della Repubblica Italiana. Serie Generale. 2004. Available from: <https://www.gazzettaufficiale.it/eli/gu/2023/07/07/157/sg/pdf>
 106. King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. *N Engl J Med* 2022;386:1687-99.
 107. Mashiko R, Oka D, Aoyama Y. Effect of JAK Inhibitor on atopic dermatitis patients associated with alopecia areata. *Nishinohon J Dermatol* 2023;85:34-7.
 108. Uchida H, Kamata M, Nagata M, et al. Baricitinib improved alopecia areata concomitant with atopic dermatitis: a case report. *J Dermatol* 2021;48:e472-3.
 109. ClinicalTrials.gov. A pilot study of tralokinumab in subjects with moderate to severe alopecia areata. Available from: <https://clinicaltrials.gov/study/NCT02684097>
 110. Chiricozzi A, Balato A, Fabbrocini G, et al. Beneficial effects of upadacitinib on alopecia areata associated with atopic dermatitis: a multicenter retrospective study. *J Am Acad Dermatol* 2023;S0190-9622(23)00765-X.
 111. Cantelli M, Martora F, Patruno C, et al. Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report. *Dermatol Ther* 2022;35:e15346.
 112. Yu D, Ren Y. Upadacitinib for successful treatment of alopecia universalis in a child: a case report and literature review. *Acta Derm Venereol* 2023;103:adv5578.
 113. Bourkas AN, Sibbald C. Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: a case report. *SAGE Open Med Case Rep* 2022;10:2050313X221138452.
 114. Bennett M, Moussa A, Sinclair R. Successful treatment of chronic severe alopecia areata with abrocitinib. *Australas J Dermatol* 2022;63:274-6.
 115. Zhao J, Liu L. A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib. *JAAD Case Rep* 2022;22:99-100.

116. Huang J, Liu O. Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib. *J Cosmet Dermatol* 2023.
117. Picone V, Napolitano M, Torta G, et al. Vitiligo during dupilumab therapy. *JAAD Case Rep* 2023;36:51-3.
118. Ren H, Akabane AL, Kelleher K, et al. Vitiligo induced by dupilumab treatment: A case series. *J Eur Acad Dermatol Venereol* 2023. Available from: <https://scholars.mssm.edu/en/publications/vitiligo-induced-by-dupilumab-treatment-a-case-series> (accessed on 18 July 2023)
119. Takeoka S, Kamata M, Yokoi I, et al. Rapid enlargement of vitiligo vulgaris after initiation of dupilumab for atopic dermatitis: a case report. *Acta Derm Venereol* 2021;101:adv00581.
120. Napolitano M, Fabbrocini G, Patrino C. Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: a retrospective study. *J Dermatol* 2023;50:880-7.
121. Pan T, Mu Y, Shi X, Chen L. Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report. *J Dermatol Treat* 2023;34:2200873.
122. Dong J, Huang X, Ma LP, et al. Baricitinib is effective in treating progressing vitiligo in vivo and in vitro. *Dose-Response Publ Int Hormesis Soc* 2022;20:1559325 8221105370.
123. Mumford BP, Gibson A, Chong AH. Repigmentation of vitiligo with oral baricitinib. *Australas J Dermatol* 2020;61:374-6.
124. Li X, Sun Y, Du J, et al. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB-UVB phototherapy. *Clin Cosmet Investig Dermatol* 2023;16:635-8.
125. Su Z, Zeng YP. Dupilumab-associated psoriasis and psoriasisiform manifestations: a scoping review. *Dermatology* 2023;1-1.
126. Gori N, Caldarola G, Pirro F, et al. A case of guttate psoriasis during treatment with dupilumab. *Dermatol Ther* 2019;32:e12998.
127. Napolitano M, Scalvenzi M, Fabbrocini G, et al. Occurrence of psoriasisiform eruption during dupilumab therapy for adult atopic dermatitis: a case series. *Dermatol Ther* 2019;32:e13142.
128. Ferrucci S, Tavecchio S, Berti E, Angileri L. Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab. *Clin Exp Dermatol* 2020;45:625-6.
129. D'Ambra I, Babino G, Fulgione E, et al. Psoriasis onset under dupilumab treatment in two patients affected by atopic dermatitis and one patient affected by alopecia areata: clinical and dermoscopic patterns. *Dermatol Ther* 2020;33.
130. Russo F, Provvidenziale L, Bruzziches F, et al. Psoriasis-like eruption triggered by dupilumab therapy. *Dermat Contact Atopic Occup Drug* 2021;32:e147-8.
131. Casale F, Nguyen C, Dobry A, et al. Dupilumab-associated psoriasis and psoriasisiform dermatitis in patients with atopic dermatitis. *Australas J Dermatol* 2022;63:394-7.
132. Brumfiel CM, Patel MH, Zirwas MJ. Development of psoriasis during treatment with dupilumab: a systematic review. *J Am Acad Dermatol* 2022;86:708-9.
133. Flanagan KE, Pupo Wiss IM, Pathoulas JT, et al. Dupilumab-induced psoriasis in a patient with atopic dermatitis and alopecia totalis: a case report and literature review. *Dermatol Ther* 2022;35:e15255.
134. Parker JJ, Sugarman JL, Silverberg NB, et al. Psoriasisiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children. *Pediatr Dermatol* 2021;38:1500-5.
135. Colonna C, Bortoluzzi P, Cavalli R. Dupilumab treatment for severe atopic dermatitis in children and SARS-CoV-2 infection: A combination of triggers for psoriasis. *J Eur Acad Dermatol Venereol* 2023;37:e568-9.
136. Varma A, Levitt J. Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis. *JAAD Case Rep* 2020;6:217-8.
137. Al Hawsawi K, AlDobokey AW, Alsulami SA, et al. Dupilumab-induced scalp psoriasis in a patient with prurigo nodularis: a case report. *Cureus* 2023. Available from: <https://www.cureus.com/articles/148198-dupilumab-induced-scalp-psoriasis-in-a-patient-with-prurigo-nodularis-a-case-report> (accessed on 19 July 2023)
138. Tracey EH, Elston C, Feasel P, et al. Erythrodermic presentation of psoriasis in a patient treated with dupilumab. *JAAD Case Rep* 2018;4:708-10.
139. Jia X, Li C, Wu J, Liu Q. Pustular psoriasis appearing induced by dupilumab therapy in a patient with atopic dermatitis. *J Drugs Dermatol JDD* 2022;21:311-2.
140. Stout M, Guitart J, Tan T, Silverberg JI. Psoriasis-like dermatitis developing in a patient with atopic dermatitis treated with dupilumab. *Dermat Contact Atopic Occup Drug* 2019;30:376-8.
141. Fowler E, Silverberg JI, Fox JD, Yosipovitch G. Psoriasisiform dermatitis after initiation of treatment with dupilumab for atopic dermatitis. *Dermat Contact Atopic Occup Drug* 2019;30:234-6.
142. Napolitano M, Caiazzo G, Fabbrocini G, B et al. Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasisiform reaction during dupilumab treatment. *Br J Dermatol* 2021;184:341-3.
143. Mirza FN, Wang A, Ramachandran SM, et al. Dupilumab-induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin-17A expression: a case report. *Br J Dermatol* 2021;185:432-4.
144. Mease PJ, Lertratanakul A, Papp KA, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled phase 3 SELECT-PsA 2 study. *Rheumatol Ther* 2021;8:903-19.
145. Gargiulo L, Ibba L, Pavia G, et al. Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series. *J Dermatol Treat* 2023;34:2183729.
146. Patrino C, Fabbrocini G, De Lucia M, et al. Psoriasisiform dermatitis induced by dupilumab successfully treated with upadacitinib. *Dermatol Ther* 2022;35:e15788.
147. Ferrucci SM, Buffon S, Marzano AV, Maronese CA. Phenotypic switch from atopic dermatitis to psoriasis during treatment with upadacitinib. *Clin Exp Dermatol* 2022;47:986-7.
148. Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. *Br J Dermatol* 2016;174:1266-76.
149. Tada Y, Ono N, Koarada S. Immediate effect of baricitinib on arthritis and biological disease-modifying antirheumatic drug-induced psoriasis-like skin lesions in two patients with rheumatoid arthritis. *Case Rep Rheumatol* 2021;2021:8876847.
150. Mansfield KE, Schmidt SAJ, Darvalics B, et al. Association between atopic eczema and cancer in England and Denmark. *JAMA Dermatol* 2020;156:1086-97.
151. Ishida M, Hodohara K, Yoshii M, et al. Primary cutaneous

- anaplastic large cell lymphoma occurring in an atopic dermatitis patient: a case report with review of the literature with emphasis on their association. *Int J Clin Exp Pathol* 2014;7:1735-41.
152. Sechi A, Guglielmo A, Patrizi A, et al. Atopic dermatitis and mycosis fungoides in a child: an overlooked association. *Ital J Dermatol Venereol* 2021;156:625-6.
 153. Owji S, Ungar B, Dubin DP, et al. No association between dupilumab use and short-term cancer development in atopic dermatitis patients. *J Allergy Clin Immunol Pract* 2023;11:1548-51.
 154. Fowler E, Rosen J, Lev-Tov H, Yosipovitch G. Two cancer patients receiving dupilumab for treatment of atopic dermatitis. *Acta Derm Venereol* 2019;99:899-900.
 155. Siliquini N, Giura MT, Viola R, et al. Atopic dermatitis, dupilumab and cancers: a case series. *J Eur Acad Dermatol Venereol* 2021;35:e651-2.
 156. Tanczosova M, Hugo J, Gkalpakiotis S. Treatment of severe atopic dermatitis with dupilumab in patients with advanced cancer. *J Clin Med* 2023;12:1191.
 157. Belmesk L, Muntyanu A, Cantin E, et al. Prominent role of Type 2 immunity in skin diseases: beyond atopic dermatitis. *J Cutan Med Surg* 2022;26:33-49.
 158. Elston DM. Dupilumab and cutaneous T-cell lymphoma. *J Am Acad Dermatol* 2020;83:33-4.
 159. Park A, Wong L, Lang A, et al. Cutaneous T-cell lymphoma following dupilumab use: a systematic review. *Int J Dermatol* 2023;62:862-76.
 160. Poyner EFM, Bacon CM, Osborne W, et al. Dupilumab unmasking cutaneous T-cell lymphoma: report of a fatal case. *Clin Exp Dermatol* 2022;47:974-6.
 161. Kolkowski K, Trzeciak M, Sokolowska-Wojdyło M. Safety and danger considerations of novel treatments for atopic dermatitis in context of primary cutaneous lymphomas. *Int J Mol Sci*. 2021;22:13388.
 162. Russomanno K, Carver DeKlotz CM. Acceleration of cutaneous T-cell lymphoma following dupilumab administration. *JAAD Case Rep* 2021;8:83-5.
 163. Espinosa ML, Nguyen MT, Aguirre AS, et al. Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients. *J Am Acad Dermatol* 2020;83:197-9.
 164. Hollins LC, Wirth P, Fulchiero GJ, Foulke GT. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. *Cutis* 2020;106:E8-11.
 165. Du-Thanh A, Gustave V, Dereure O. Lethal anaplastic large-cell lymphoma occurring in a patient treated with dupilumab. *JAAD Case Rep* 2021;18:4-7.
 166. Saad S, Ram-Wolff C, De Masson A, et al. CD30-positive anaplastic large-cell lymphoma associated with mycosis fungoides after treatment with dupilumab. *Eur J Dermatol EJD* 2022;32:536-7.
 167. Ahatov R, Good AJ, Joo M, et al. A rare case of aggressive cytotoxic T-cell lymphoma in a patient on dupilumab. *JAAD Case Rep* 2022;24:112-4.
 168. Choo ZY, Akinyemi AA, Cibull T, et al. Angioimmunoblastic T-cell lymphoma unmasked by treatment with dupilumab. *JAAD Case Rep* 2023;33:87-90.
 169. Nakazaki K, Yoshida M, Masamoto Y, et al. Discordant lymphomas of classic Hodgkin lymphoma and peripheral T-cell lymphoma following dupilumab treatment for atopic dermatitis. *Int J Hematol* 2022;116:446-52.
 170. Blauvelt A, Langley RG, Lacour JP, et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZ-TEND open-label extension trial. *J Am Acad Dermatol* 2022;87:815-24.
 171. Samuel C, Cormman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. *Dermatol Ther* 2023;13:729-49.
 172. European Medicines Agency. Janus kinase inhibitors (JAKi) - referral. Available from: <https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki>
 173. Ytterberg SR, Bhatt DL, Connell CA. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. Reply. *N Engl J Med* 2022;386:1768.
 174. Balakirski G, Novak N. Atopic dermatitis and pregnancy. *J Allergy Clin Immunol* 2022;149:1185-94.
 175. Khamisy-Farah R, Damiani G, Kong JD, et al. Safety profile of Dupilumab during pregnancy: a data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase™). *Eur Rev Med Pharmacol Sci* 2021;25:5448-51.
 176. Escolà H, Figueras-Nart I, Bonfill-Orti M, et al. Dupilumab for atopic dermatitis during pregnancy and breastfeeding: Clinical experience in 13 patients. *J Eur Acad Dermatol Venereol* 2023.
 177. Gracia-Darder I, Pons De Ves J, Reyero Cortina M, Martín-Santiago A. Patient with atopic dermatitis, hyper IgE syndrome and ulcerative colitis, treated successfully with dupilumab during pregnancy. *Dermatol Ther* 2022;35:e15237.
 178. L Ramos C, Namazy J. Monoclonal antibodies (biologics) for allergic rhinitis, asthma, and atopic dermatitis during pregnancy and lactation. *Immunol Allergy Clin North Am* 2023;43:187-97.
 179. Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Lond Engl*. 2022;400:908-19.
 180. Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. *J Am Acad Dermatol* 2020;83:1282-93.
 181. Stingeni L, Bianchi L, Antonelli E, et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. *J Eur Acad Dermatol Venereol* 2022;36:1292-9.
 182. Paller AS, Flohr C, Cork M, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. *JAMA Dermatol* 2023;159:596-605.
 183. Silverberg JI, de Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. *J Allergy Clin Immunol* 2022;149:977-87.e14.
 184. Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. *JAMA Dermatol* 2022;158:404-13.
 185. Paller AS, Ladizinski B, Mendes-Bastos P, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the Measure Up 1, Measure Up 2, and AD Up randomized clinical trials. *JAMA Dermatol* 2023;159:526-35.
 186. De Greef A, Ghislain PD, de Montjoye L, Baeck M. Real-life

- effectiveness and tolerance of upadacitinib for severe atopic dermatitis in adolescents and adults. *Adv Ther* 2023;40:2509-14.
187. Cork MJ, McMichael A, Teng J, et al. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. *J Eur Acad Dermatol Venereol* 2022;36:422-33.
188. Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN Randomized Clinical Trial. *JAMA Dermatol* 2021;157:1165-73.
189. Torreló A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). *Br J Dermatol* 2023;189:23-32.
190. Tanei R, Hasegawa Y. Atopic dermatitis in older adults: a viewpoint from geriatric dermatology. *Geriatr Gerontol Int* 2016;16:75-86.
191. Chello C, Carnicelli G, Sernicola A, et al. Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature. *Int J Dermatol* 2020;59:716-21.
192. Lam M, Zhu JW, Maqbool T, et al. Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: a systematic review. *JAMA Dermatol* 2020;156:1240-5.
193. Napolitano M, Fabbrocini G, Scalvenzi M, et al. Efficacy and safety of dupilumab in atopic dermatitis in elderly patients: a retrospective study. *Clin Exp Dermatol* 2020;45:888-90.
194. Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. *J Eur Acad Dermatol Venereol* 2021;35:958-64.
195. Patruno C, Fabbrocini G, Longo G, et al. Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study. *Am J Clin Dermatol* 2021;22:581-6.
196. LEO Pharma announces FDA approval of Adbry™ (tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis. Available from: <https://www.businesswire.com/news/home/20211227005159/en/LEO-Pharma-announces-FDA-approval-of-Adbry%E2%84%A2-tralokinumab-ldrm-as-the-first-and-only-treatment-specifically-targeting-IL-13-for-adults-with-moderate-to-severe-atopic-dermatitis>
197. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. *Lancet Lond Engl* 2021;397:2151-68.
198. Reich K, Kabashima K, Peris K, et al. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis. *JAMA Dermatol* 2020;156:1-11.